NCT04445051

Brief Summary

Investigation of non-CE marked intermittent catheters. The study was a randomized, single blinded, cross-over investigation comparing two new catheters with a comparator catheter in 30 adult healthy volunteers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2020

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 28, 2020

Completed
27 days until next milestone

First Posted

Study publicly available on registry

June 24, 2020

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2020

Completed
2.8 years until next milestone

Results Posted

Study results publicly available

July 3, 2023

Completed
Last Updated

July 3, 2023

Status Verified

August 1, 2022

Enrollment Period

6 months

First QC Date

May 28, 2020

Results QC Date

February 4, 2022

Last Update Submit

August 8, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Residual Urine at 1st Flow-stop

    The residual urine at 1st flow-stop during catheterization (performed by a nurse) represents the volume of urine left in the bladder, the first time the urine stops running out of the catheter during bladder emptying/urination. This was assessed using a pressure sensor with time-logged weighing, meaning that a flow-stop was registered measuring the hydrostatic pressure at the outlet of an intermittent urinary catheter. Simultaneously, the collected urine was weighed and converted to volume, and the residual volume at first flow stop was calculated as the difference between the total urine volume collected and the volume collected at the first flow-stop.

    Immediately after the procedure/catheterization, up to 5 min.

Secondary Outcomes (6)

  • Post-void Residual Urine

    Immediately after the procedure/catheterization, up to 15 min.

  • Catheterization Insertion Discomfort

    Immediately after the procedure/catheterization, up to 5 min.

  • Catheterization Urination Discomfort

    Immediately after the procedure/catheterization, up to 5 min.

  • Withdrawal Discomfort

    Immediately after the procedure/catheterization, up to 5 min.

  • Overall Catheterization Discomfort

    Immediately after the procedure/catheterization, up to 5 min.

  • +1 more secondary outcomes

Study Arms (3)

Intermittent catheter; SpeediCath® Standard male or female

ACTIVE COMPARATOR

Participants underwent catheterization with standard of care intermittent catheter. The catheterization was performed by a trained nurse.

Device: SpeediCath® Standard male or female

New intermittent catheter Variant 1 for male or female

EXPERIMENTAL

Participants underwent catheterization with the new intermittent catheter Variant 1 for males or females. The catheterization was performed by a trained nurse.

Device: New intermittent Variant 1 catheter for male or female

New intermittent catheter Variant 2 for male or female

EXPERIMENTAL

Participants underwent catheterization with the new intermittent catheter Variant 2 for males or females. The catheterization was performed by a trained nurse.

Device: New intermittent Variant 2 catheter for male or female

Interventions

Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male or female.

Intermittent catheter; SpeediCath® Standard male or female

Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 for male or female.

New intermittent catheter Variant 1 for male or female

Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 for male or female.

New intermittent catheter Variant 2 for male or female

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Minimum 18 years of age and with full legal capacity
  • Written informed consent and signed letter of authority and secrecy agreement given
  • Willing to comply with not using analgesics 1 up to 24 hours prior to catheterization visits
  • Urine Multistix negative for erythrocytes (hematuria)

You may not qualify if:

  • Participation in any other clinical investigations during this investigation
  • Known hypersensitivity towards any of the test products
  • Symptoms of urinary tract infection (UTI) (Investigators judgement)
  • Pregnancy or breastfeeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Urologisk klinik, Afsnit 2112, Rigshospitalet

Copenhagen, Copenhagen Ø, 2100, Denmark

Location

Related Publications (1)

  • Landauro MH, Tentor F, Pedersen T, Jacobsen L, Bagi P. Improved Performance With the Micro-Hole Zone Intermittent Catheter: A Combined Analysis of 3 Randomized Controlled Studies Comparing the New Catheter Technology With a Conventional Eyelet Catheter. J Wound Ostomy Continence Nurs. 2023 Nov-Dec 01;50(6):504-511. doi: 10.1097/WON.0000000000001029.

MeSH Terms

Conditions

Urinary Retention

Condition Hierarchy (Ancestors)

Urination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Results Point of Contact

Title
Vice President, Medical Affairs
Organization
Coloplast A/S

Study Officials

  • Per Bagi, MD

    Blegdamsvej 9, Urologisk klinik Afsnit 2112, Rigshospitalet, Denmark

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 28, 2020

First Posted

June 24, 2020

Study Start

March 1, 2020

Primary Completion

September 1, 2020

Study Completion

September 1, 2020

Last Updated

July 3, 2023

Results First Posted

July 3, 2023

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will not share

Locations